Hemostemix Inc. (CVE:HEM – Get Free Report) Director Peter Alan Lacey bought 200,000 shares of Hemostemix stock in a transaction that occurred on Thursday, March 6th. The stock was purchased at an average price of C$0.15 per share, with a total value of C$30,000.00.
Peter Alan Lacey also recently made the following trade(s):
- On Wednesday, February 26th, Peter Alan Lacey sold 96,464 shares of Hemostemix stock. The shares were sold at an average price of C$0.18, for a total value of C$16,881.20.
Hemostemix Trading Down 3.4 %
Shares of CVE:HEM opened at C$0.14 on Monday. The business has a 50-day moving average price of C$0.22 and a 200-day moving average price of C$0.13. The stock has a market cap of C$20.40 million, a price-to-earnings ratio of -4.08 and a beta of 0.20. Hemostemix Inc. has a 52-week low of C$0.04 and a 52-week high of C$0.43. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Ride Out The Recession With These Dividend Kings
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
